Video
AHA 2026: Lp(a)HORIZON, pelacarsen and cardiovascular outcomes, the take-home messages (Steven Nissen)
In this second, shorter conversation Steven Nissen (Cleveland Clinic) sums up Lp(a)HORIZON: pelacarsen lowered lipoprotein(a) by 78 percent in 8,322 patients with established cardiovascular disease, but cardiovascular outcomes did not differ from placebo (hazard ratio 1.02 for the primary endpoint). What the result means for the Lp(a) hypothesis, for the ongoing outcomes trials of other agents, and for the patient with a high Lp(a) in the consulting room. Presented in LBS.01 on 7 November 2026 and published in NEJM. Recorded at AHA Scientific Sessions 2026 by Radcliffe Cardiology.
aha 2026lpa horizonoutcomes trialpelacarsenphase 3RNA therapeuticssecondary prevention
Player and playback by Radcliffe Cardiology; the framing above is lp-a.org's. Page updated 10 November 2026.